Cannabinoid-based Finished Drug Development
Throughout medical history, every major discovery of a physiological regulatory system has led to the identification of new therapeutic targets, unlocking innovative treatments that reshape patient care. The endocannabinoid system (ECS) is among the most recently recognized and characterized biological systems, playing a fundamental role in homeostasis, immune modulation, pain regulation, and neurological function.
Today, we stand at the precipice of a new medical frontier – the integration of cannabinoid-based therapies into modern medicine. By targeting the ECS with precisely characterized active compounds, we have the opportunity to address some of the most complex, underserved, and treatment-resistant conditions.
Neuropathology, the healthcare gap of modern society.
Neurological disorders affect over 1/3 of the global population, making them the 2nd leading cause of disability, and the leading cause of disability-adjusted life years globally. Treatments are often limited, ineffective and have a high risk profile with potential for addiction.
A unique clinical opportunity, to apply phytocannabinoids
80% of neurological disorders show ECS dysregulation. Therefore, cannabinoid-based medicines present a unique clinical opportunity. Phytocannabinoids’ multifaceted action on the nervous system makes them highly versatile for managing complex neurological medical conditions, through: Modulation of Neurotransmitters, Anti-inflammatory Effects, Pain Management, Neuroprotection and Mood and Anxiety Regulation.
Our clinical pipeline
Cannaflos has built a robust, scientifically validated drug development pipeline focused on Neuropathology.
We are currently focusing on two high-potential indications, each supported by validated regulatory pathways through direct engagement with regulatory agencies.
Recognizing the complexity of the endocannabinoid system and respecting individual differences is crucial in designing clinical trials with phytocannabinoids. This approach is key to successful trials, ultimately advancing patient care and outcomes.
Meike Meinzer
Head of Drug Development
Biologist with focus on phytomedicine
Expert cannabinoids and their therapeutic use
Scientific and clinical conceptualisation
Clinical R&D services
We offer our R&D platform to enable the drug development of third party pharmaceutical companies.
We engage our expertise, partners, and network to accelerate your drug development process.
